Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,571.4040.30-0.47%
CAC 407,818.9291.57-1.16%
DAX 4023,860.73261.67-1.08%
Dow JONES (US)41,860.44816.80-1.91%
FTSE 1008,708.0078.46-0.89%
HKSE23,544.31283.47-1.19%
NASDAQ18,872.64270.07-1.41%
Nikkei 22536,985.87313.11-0.84%
NZX 50 Index12,662.2540.85-0.32%
S&P 5005,844.6195.85-1.61%
S&P/ASX 2008,348.7038.10-0.45%
SSE Composite Index3,380.197.39-0.22%

Market Movers